{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Elevar+Therapeutics",
    "query": {
      "sponsor": "Elevar Therapeutics"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T04:15:59.465Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03396211",
      "title": "A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Apatinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-12-22",
      "completion_date": "2022-03-16",
      "has_results": false,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03396211"
    },
    {
      "nct_id": "NCT03407976",
      "title": "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Urothelial Carcinoma",
        "MSI-H or dMMR Solid Tumors",
        "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Apatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-06-19",
      "completion_date": "2020-07-02",
      "has_results": false,
      "last_update_posted_date": "2020-07-15",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03407976"
    },
    {
      "nct_id": "NCT04119453",
      "title": "A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Rivoceranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2020-01-22",
      "completion_date": "2023-06-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04119453"
    },
    {
      "nct_id": "NCT07359820",
      "title": "A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FGFR2 Gene Fusion/Rearrangement",
        "Other Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "Lirafugratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-04",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07359820"
    },
    {
      "nct_id": "NCT03042611",
      "title": "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastric Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Rivoceranib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2017-03-14",
      "completion_date": "2020-09-23",
      "has_results": true,
      "last_update_posted_date": "2022-07-08",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03042611"
    },
    {
      "nct_id": "NCT04073615",
      "title": "A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Rivoceranib",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine/Tipiracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2019-11-18",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 4,
      "location_summary": "Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04073615"
    },
    {
      "nct_id": "NCT01497704",
      "title": "Dose-Escalation and Safety Trial of YN968D1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer Patients With Solid Tumors"
      ],
      "interventions": [
        {
          "name": "YN968D1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2012-04",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2017-10-02",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497704"
    },
    {
      "nct_id": "NCT05287360",
      "title": "A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rivoceranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-12-30",
      "completion_date": "2022-03-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05287360"
    },
    {
      "nct_id": "NCT04526106",
      "title": "REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "FGFR2 Amplification",
        "FGFR2 Gene Mutation",
        "FGFR2 Gene Fusion/Rearrangement",
        "FGFR2 Gene Translocation",
        "FGFR2 Gene Activation",
        "Intrahepatic Cholangiocarcinoma",
        "Cholangiocarcinoma",
        "Other Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "RLY-4008",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2020-09-02",
      "completion_date": "2025-09-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-02T04:15:59.465Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04526106"
    }
  ]
}